Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting

Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting

Bibliographic Details
Main Authors:	F. Roghmann, R. Wirtz, A. Santiago-Walker, J. Jarczyk, M.C. Kriegmair, T.S. Worst, D. Sikic, S. Wach, H. Taubert, V. Weyerer, R. Stoehr, K. Tully, F. Zengerling, C. Bolenz, J. Breyer, M. Burger, S. Porubsky, A. Hartmann, P. Erben, M. Eckstein, H. Jütte
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320331372

Similar Items

The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
by: Sikic D, et al.
Published: (2021-08-01)

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
by: Alec Kacew, et al.
Published: (2020-11-01)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
by: Nadia Carvalho Lima, et al.
Published: (2020-05-01)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
by: Se Hyun Kim, et al.
Published: (2018-10-01)

Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an <i>FGFR3</i> Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype
by: Veronika Weyerer, et al.
Published: (2020-03-01)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
by: Hodgson-Garms, M., et al.
Published: (2022)

Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma
by: Ming-Dow Tsay, et al.
Published: (2019-12-01)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
by: Álvaro Quintanal-Villalonga, et al.
Published: (2020-03-01)

mRNA-Expression of <em>KRT5</em> and <em>KRT20</em> Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants
by: Markus Eckstein, et al.
Published: (2018-10-01)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
by: Cong Wang, et al.
Published: (2019-01-01)

FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy
by: Danijel Sikic, et al.
Published: (2020-04-01)

Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
by: Young Saing Kim, et al.
Published: (2018-07-01)

High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer
by: Danijel Sikic, et al.
Published: (2021-06-01)

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts
by: Danijel Sikic, et al.
Published: (2019-04-01)

In Vivo, In Vitro, and In Silico approaches identify FGFR-dependent and FGFR-independent mechanisms for lens development
by: Padula, Stephanie Lucia
Published: (2020)

Effects of FGFR1 Gene Polymorphisms on the Risk of Breast Cancer and FGFR1 Protein Expression
by: Junqiang Wu, et al.
Published: (2018-07-01)

Association study of five mutation in FGFR1 and FGFR2 genes in Indian children with craniosynostosis
by: Pandey Rajeev Kumar, et al.
Published: (2013-01-01)

Impact of FGFR3 genomic aberrations in patients with metastatic urothelial carcinoma treated with first line platinum-based chemotherapy
by: R. Morales Barrera, et al.
Published: (2020-07-01)

FGFR1 is a potential therapeutic target in neuroblastoma
by: Avitabile, M., et al.
Published: (2022)

Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy
by: Arndt Hartmann, et al.
Published: (2020-06-01)

Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer
by: Leisl M. Packer, et al.
Published: (2019-04-01)

Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling
by: Brian D. Robinson, et al.
Published: (2019-07-01)

Urothelial carcinoma of the upper urinary tract diagnosed via <it>FGFR3</it> mutation detection in urine: a case report
by: Silverberg Daniel M
Published: (2012-08-01)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
by: Ying Yang, et al.
Published: (2020-01-01)

Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
by: Chaofeng Yang, et al.
Published: (2012-01-01)

Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study
by: Qureshi Abrar A, et al.
Published: (2009-06-01)

The Function of FGFR1 Signalling in the Spinal Cord: Therapeutic Approaches Using FGFR1 Ligands after Spinal Cord Injury
by: Barbara Haenzi, et al.
Published: (2017-01-01)

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
by: Mikkel G. Terp, et al.
Published: (2021-07-01)

KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer
by: Hendrik Jütte, et al.
Published: (2021-05-01)

Prospects of therapeutic action on FGFR signaling pathway
by: M. Yu. Fedyanin, et al.
Published: (2015-06-01)

Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.
by: Daichao Wu, et al.
Published: (2016-01-01)

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
by: Ying X, et al.
Published: (2019-11-01)

Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors
by: Yuan Li, et al.
Published: (2020-01-01)

ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.
by: Cristina Balbás-Martínez, et al.
Published: (2013-01-01)

THE IMMUNOEXPRESSION PROFILE OF FGFR3 AND P53 IN PUNLMP AND UROTHELIAL BLADDER CARCINOMA AT HASAN SADIKIN GENERAL HOSPITAL
by: Sri Suryanti, et al.
Published: (2020-07-01)

Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
by: Veronika Weyerer, et al.
Published: (2021-05-01)

Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases
by: Leomar Y. Ballester, et al.
Published: (2019-04-01)

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
by: Hong Yuan, et al.
Published: (2017-05-01)

Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas
by: Birgitta Lehtinen, et al.
Published: (2017-05-01)

Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs
by: Maria-Magdalena Georgescu, et al.
Published: (2021-04-01)